Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT03880396 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN

Start date: March 10, 2019
Phase:
Study type: Observational

The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.

NCT ID: NCT03878979 Completed - Clinical trials for Head and Neck Cancer

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Start date: July 8, 2019
Phase: Phase 2
Study type: Interventional

Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).

NCT ID: NCT03877159 Recruiting - Oral Cancer Clinical Trials

Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma

Start date: November 11, 2017
Phase:
Study type: Observational

Control of cell death is frequently disrupted in cancer resulting in overgrowth of tumour cells. Caspase-8 is a key enzyme involved in controlling cell death. This study examines the importance of caspase-8 in oral cancer.

NCT ID: NCT03875859 Terminated - Clinical trials for Squamous Cell Carcinoma

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.

NCT ID: NCT03875716 Recruiting - Clinical trials for Head and Neck Cancer

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Start date: May 20, 2019
Phase: N/A
Study type: Interventional

This research study is studying lowering the standard dose of radiation and chemotherapy after surgery, to minimize the side effects and improve the quality of life.

NCT ID: NCT03875053 Withdrawn - Clinical trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer

Start date: July 25, 2023
Phase: N/A
Study type: Interventional

This trial studies information from a home sleep apnea machine to evaluate obstructive sleep apnea in patients with stage III-IV head and neck cancer. Sleep apnea (trouble breathing during sleep) can occur in head and neck cancer patients who have swelling in their neck. Wearing a sleep apnea machine overnight may help doctors evaluate obstructive sleep apnea in patients with head and neck cancer.

NCT ID: NCT03874741 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Start date: May 21, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody#SCT200#and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

NCT ID: NCT03868020 Completed - Clinical trials for Metastatic Head and Neck Squamous Cell Carcinoma

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Start date: April 24, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has spread to the cervical lymph nodes. Fluciclovine F18 during a PET/CT scan may work better in helping doctors learn where the cancer started (called the site of origin) and directing treatment planning compared to standard fludeoxyglucose F-18 (FDG) PET-CT scans.

NCT ID: NCT03866382 Recruiting - Clinical trials for Stage IVB Prostate Cancer AJCC v8

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Start date: May 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

NCT ID: NCT03857763 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.